Intravenous Immunoglobulin Home Treatment for Patients With Primary Immunodeficiency Diseases

Ochs, HansD.; Fischer, Susanna; Lee, MartinL.; Delson, E; Kingdon, HenryS.; Wedgwood, RalphJ.

doi:10.1016/s0140-6736(86)92826-6

Cited by 35 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quality of life is recognized as the patient's perception of the impact of disease and treatment on daily life. Previous studies have demonstrated an improved quality of life because of decreased time loss from school or work, lower costs, greater independence, better knowledge of their condition, fewer interruptions with daily activities, increased self-confidence, and better disease management (Sorensen et al 1897;Ochs et al 1986;Sigstad et al 2005;Bhole et al 2008). Surprisingly, patients in our study ranked quality of life as second last in terms of convenience for home therapy (Table 5).…”

Section: Quality Of Lifecontrasting

confidence: 45%

“…This may reflect patients' anxiety over fewer doctor visits (Table 6, ranked second for inappropriateness) for patients under 35 years of age as well as for parents and patients at teaching hospitals. Some of these concerns may be alleviated by robust training and education of patients, association to an infusion center, and access to national patient PID organizations (Asthida and Saxon 1986;Ochs et al 1986;Ochs et al 1987;Sorensen et al 1987;Chapel et al 1988;Kobayashi et al 1990;Brennan et al 1995;Sigstad et al 2005;Bhole et al 2008). …”

Section: Preferencesmentioning

confidence: 99%

See 1 more Smart Citation

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

ReidBrenda

PiresLinda

2014

LymphoSign Journal

View full text Add to dashboard Cite

Introduction: For close to half a century immunoglobulin replacement therapy has been the main therapy for patients unable to produce functioning antibodies. To date, both subcutaneous (SC) and intravenous delivery methods have been successful at effectively and safely replacing immunoglobulin. Home intravenous and SC therapy programs have been established and have gained attention, but the true motivation and frequency of switching from traditional hospital-based treatment to these alternatives remains unknown. This study aims to determine the willingness of patients in Canada to switch to a home-based gammaglobulin treatment program by quantifying related experiences and preferences.

show abstract

Section: Quality Of Lifecontrasting

confidence: 45%

Section: Preferencesmentioning

confidence: 99%

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

ReidBrenda

PiresLinda

2014

LymphoSign Journal

View full text Add to dashboard Cite

show abstract

“…Many centres provide training in SCIg and IVIg home therapy, which has clear benefits for patients, such as increased lifestyle flexibility and taking control of the management of their disease [87][88][89].…”

Section: Choice Of Product and Administration Routementioning

confidence: 99%

Immunoglobulin treatment in primary antibody deficiency

Maarschalk-Ellerbroek

Hoepelman

Ellerbroek

2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

The primary antibody deficiency syndromes are characterised by recurrent respiratory tract infections and the inability to produce effective immunoglobulin (Ig) responses. The best known primary antibody deficiencies are common variable immunodeficiency (CVID), X-linked agammaglobulinaemia (XLA), immunoglobulin G (IgG) subclass deficiency, and selective antibody deficiency with normal immunoglobulins (SADNI).Therapy in these patients consists of prophylactic antibiotics and/or Ig replacement therapy. Diagnostic delay remains common owing to limited awareness of the presenting features and may result in increased morbidity and mortality. Replacement therapy with immunoglobulins increases life expectancy and reduces the frequency and severity of infections, but the effect on end-organ damage is still unknown. Both intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) treatment appear to be safe, with comparable efficacy. A starting dose of 300-400 mg/kg/month in IVIg and 100 mg/week for SCIg is recommended. IgG trough levels should be >5 g/L for patients with agammaglobulinaemia and 3 g/L greater than the initial IgG level for patients with CVID; however, the clinical response should be foremost in choosing the dose and trough level. Infusion-related adverse reactions are generally mild owing to improved manufacturing processes. In this paper, aspects of Ig replacement therapy in primary antibody-deficient patients will be addressed.

show abstract

“…In those patients with humoral immunodeficiency, antibody production is decreased or of poor quality, leading to severe, recurrent infections that are predominantly bacterial sinopulmonary infections [1]. Historically, lifelong treatment of these types of PID with immunoglobulin (Ig) through various routes (e.g., intravenous (IV), subcutaneous (SC), intramuscular) has been wellestablished and has been shown to decrease the incidence of infections in these patients [1][2][3][4][5][6][7][8][9][10]. Moreover, SCIg therapy has been shown through several studies to be effective, safe, and well-tolerated in patients with PID [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

Intravenous Immunoglobulin Home Treatment for Patients With Primary Immunodeficiency Diseases

Cited by 35 publications

References 3 publications

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada

Immunoglobulin treatment in primary antibody deficiency

Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease

Contact Info

Product

Resources

About